The HrC Test
Resources
Early detection saves lives
Earlier detection changes them
Indian Clinical Study, 2018
In 2018, a double-blinded, CTRI registered, 1,000-subject clinical study was conducted in India, encompassing over 25 different types of cancer and investigated the potential of pluripotency markers for cancer diagnosis.
In a prior study of 120 known cancer patients, it was observed that pluripotency expression in peripheral blood correlated well with the absence, imminence, or presence of cancer, and if present, it correlated with its indicative stage. Based on these results, a proprietary HrC Scale was developed wherein the fold-change of onco-biomarkers was linked to patient status.
As a result of this study, the following paper was published in Stem Cell Reviews and Reports:
‘Quest for Pan-Cancer Diagnosis/Prognosis Ends with HrC Test Measuring Oct4A in Peripheral Blood’
Clinical Study Overview
Oxford University Press, March 2023
In March 2023, Tzar Labs published the following paper in Oxford University Press, which discloses the science behind the technology:
‘Very Small Embryonic-Like Stem Cells Transform Into Cancer Stem Cells and are Novel Candidates for Detecting/Monitoring Cancer by a Simple Blood Test’